Will adaptive design become the new paradigm for cancer trials?
No one in biotech – industry, academia, regulators, nonprofits or patients themselves – disputes that cancer drug development is at a critical juncture. A raft of young companies has joined early movers in the space and the pipeline is filled with promising drugs.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter